The Transferrin Receptor-Directed CAR for the Therapy of Hematologic Malignancies
As many patients ultimately relapse after chimeric antigen receptor (CAR) T-cell therapy, identification of alternative targets is currently being evaluated. Substantial research efforts are underway to develop new targets. The transferrin receptor (TfR) is prevalently expressed on rapidly prolifera...
| Main Authors: | , , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
Frontiers Media S.A.
2021-03-01
|
| 叢編: | Frontiers in Immunology |
| 主題: | |
| 在線閱讀: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.652924/full |